Intellipharmaceutics International Inc. (IPCI)

[fred198484]

Short blurb from a Mackie report today (bolding added by me):

Rexista Should Be The Best-in-Class Oxycodone and Grasp Decent Market Share: We believe regulations for opioids are likely going to be more strictly enforced based on recent FDA events (the FDA asked Endo to remove Opana ER from the market and issued a complete response letter (CRL) to Egalet regarding the prior approval supplement (PAS) of Oxaydo, as well, a public FDA meeting on July 10th and 11th is also to be held regarding
opioid drugs with abuse-deterrent properties). We believe IPCI’s Rexista has the most disruptive technologies to prevent opioid abuse in the category of oxycodone to date and based on that it should obtain a decent share in the opioid market once launched. We expect Rexista to be U.S. launched in 2018 after IPCI resolves the patent dispute with Purdue. IPCI
needs to find a strong U.S. marketing partner to showcase this product.

IMPACT – Maintaining our SPECULATIVE BUY rating and US$6 TP